{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:36Z","timestamp":1791449436594,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01916-6","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:48:09Z","timestamp":1789141689000},"page":"4897-4912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Expanding Role of GLP-1 Receptor Agonists and Dual GIP\/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice"],"prefix":"10.1007","volume":"16","author":[{"given":"Caterina M.","family":"Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3203-6499","authenticated-orcid":false,"given":"Carola","family":"Roman\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Arisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mezzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grigolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Licata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"21","key":"1916_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751","volume":"135","author":"CK Wong","year":"2025","unstructured":"Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025;135(21):e194751. https:\/\/doi.org\/10.1172\/JCI194751.","journal-title":"J Clin Invest"},{"key":"1916_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.088","author":"S Narla","year":"2026","unstructured":"Narla S, Narla RR, Corbett JA. JAAD CME Part 1: mechanism of action of GLP-1 receptor agonists and potential pathways in skin health. J Am Acad Dermatol. 2026. https:\/\/doi.org\/10.1016\/j.jaad.2026.01.088.","journal-title":"J Am Acad Dermatol"},{"key":"1916_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. https:\/\/doi.org\/10.3389\/fimmu.2023.1148209.","journal-title":"Front Immunol"},{"key":"1916_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cytogfr.2026.01.003","volume":"88","author":"J Jang","year":"2026","unstructured":"Jang J, Park M, Kim HJ, et al. Reprogramming immunity at the metabolic-epidermal interface in obesity-associated psoriasis. Cytokine Growth Factor Rev. 2026;88:32\u201346. https:\/\/doi.org\/10.1016\/j.cytogfr.2026.01.003.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1916_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20694","author":"IA Paschou","year":"2025","unstructured":"Paschou IA, Sali E, Paschou SA, et al. The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20694.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1916_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010046","volume":"15","author":"J Petkovi\u0107-Dabi\u0107","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107 J, Bini\u0107 I, Cari\u0107 B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15(1):46. https:\/\/doi.org\/10.3390\/biom15010046.","journal-title":"Biomolecules"},{"key":"1916_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1801203","volume":"17","author":"YL Chiang","year":"2026","unstructured":"Chiang YL, Li TH, Fang YW, et al. Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation. Front Endocrinol (Lausanne). 2026;17:1801203. https:\/\/doi.org\/10.3389\/fendo.2026.1801203.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"21","key":"1916_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292. https:\/\/doi.org\/10.3390\/jcm13216292.","journal-title":"J Clin Med"},{"issue":"12","key":"1916_CR9","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","volume":"145","author":"J Ghebrehiwet-Kuflom","year":"2025","unstructured":"Ghebrehiwet-Kuflom J, Mehta A, Lim P, et al. GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing. J Invest Dermatol. 2025;145(12):2981\u201391. https:\/\/doi.org\/10.1016\/j.jid.2025.08.045.","journal-title":"J Invest Dermatol"},{"issue":"39","key":"1916_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405987","volume":"11","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhang C, Kang C, et al. Liraglutide promotes diabetic wound healing via Myo1c\/Dock5. Adv Sci. 2024;11(39):e2405987. https:\/\/doi.org\/10.1002\/advs.202405987.","journal-title":"Adv Sci"},{"key":"1916_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70382","author":"S Taj","year":"2025","unstructured":"Taj S, et al. Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: insights from meta-analysis of randomised controlled trials and real-world evidence. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.70382.","journal-title":"Diabetes Obes Metab"},{"key":"1916_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2026.113333","volume":"237","author":"PL Cheng","year":"2026","unstructured":"Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333. https:\/\/doi.org\/10.1016\/j.diabres.2026.113333.","journal-title":"Diabetes Res Clin Pract"},{"key":"1916_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1744308","volume":"17","author":"G Ciancio","year":"2026","unstructured":"Ciancio G, Maranini B, Sandri G, et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Front Immunol. 2026;17:1744308. https:\/\/doi.org\/10.3389\/fimmu.2026.1744308.","journal-title":"Front Immunol"},{"issue":"2","key":"1916_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/00368504261444578","volume":"109","author":"AK Gupta","year":"2026","unstructured":"Gupta AK, Teasell EM, Economopoulos V, et al. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2):00368504261444578. https:\/\/doi.org\/10.1177\/00368504261444578.","journal-title":"Sci Prog"},{"key":"1916_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023","author":"D Mozaffarian","year":"2025","unstructured":"Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.04.023.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1916_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/ohn.1209","volume":"173","author":"RK Sharma","year":"2025","unstructured":"Sharma RK, Vittetoe KL, Barna AJ, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngol Head Neck Surg. 2025;173(2):360\u20136. https:\/\/doi.org\/10.1002\/ohn.1209.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"1916_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/asj\/sjaf240","volume":"46","author":"ZP Lorenc","year":"2026","unstructured":"Lorenc ZP, Somenek M, Nguyen TQ, et al. A multicenter, open-label study of combined poly-L-lactic acid and hyaluronic midface filler regimen enhances facial harmony and skin quality in GLP-1 medication users. Aesthet Surg J. 2026;46(5):509\u201319. https:\/\/doi.org\/10.1093\/asj\/sjaf240.","journal-title":"Aesthet Surg J"},{"key":"1916_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01699-w","author":"A Moradi","year":"2026","unstructured":"Moradi A, Kim JH, Kim JM, et al. Clinical efficacy of a Flavo-Proxylane topical regimen pre- and post-ultrasound procedure for subjects undergoing glucagon-like peptide 1 (GLP-1) receptor agonist therapy. Dermatol Ther (Heidelb). 2026. https:\/\/doi.org\/10.1007\/s13555-026-01699-w.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1916_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/clinem\/dgad532","volume":"109","author":"GR Mullins","year":"2024","unstructured":"Mullins GR, Hodsdon ME, Li YG, et al. Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies. J Clin Endocrinol Metab. 2024;109(2):361\u201377. https:\/\/doi.org\/10.1210\/clinem\/dgad532.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1916_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388. https:\/\/doi.org\/10.2337\/dci24-0003.","journal-title":"Diabetes Care"},{"issue":"5","key":"1916_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18050605","volume":"18","author":"K Andrzejczak","year":"2026","unstructured":"Andrzejczak K, Kucharczyk E, Korgiel M, et al. GLP-1 receptor agonists in chronic inflammatory skin diseases: immunometabolic mechanisms and translational perspectives. Pharmaceutics. 2026;18(5):605. https:\/\/doi.org\/10.3390\/pharmaceutics18050605.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1916_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","volume":"162","author":"S Sheth","year":"2026","unstructured":"Sheth S, Merola JF, Weber BN, et al. The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review. JAMA Dermatol. 2026;162(6):619\u201330. https:\/\/doi.org\/10.1001\/jamadermatol.2026.0859.","journal-title":"JAMA Dermatol."},{"issue":"6 Suppl","key":"1916_CR23","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/DSS.0000000000005187","volume":"52","author":"K Vyas","year":"2026","unstructured":"Vyas K, Gopinath S, Dacso M, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists and cutaneous biology: implications for skin disease and longevity. Dermatol Surg. 2026;52(6 Suppl):S45\u201354. https:\/\/doi.org\/10.1097\/DSS.0000000000005187.","journal-title":"Dermatol Surg"},{"issue":"26","key":"1916_CR24","doi-asserted-by":"publisher","first-page":"00241","DOI":"10.1016\/j.jaad.2026.01.089","volume":"S0190\u20139622","author":"S Narla","year":"2026","unstructured":"Narla S, Narla RR. JAAD CME Part 2: Clinical evidence and safety considerations for GLP-1 receptor agonists in dermatology. J Am Acad Dermatol. 2026;S0190\u20139622(26):00241. https:\/\/doi.org\/10.1016\/j.jaad.2026.01.089.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"1916_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1916_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamadermatol.2026.1753","volume":"162","author":"M Lebwohl","year":"2026","unstructured":"Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial. JAMA Dermatol. 2026;162(7):709\u201319. https:\/\/doi.org\/10.1001\/jamadermatol.2026.1753.","journal-title":"JAMA Dermatol"},{"key":"1916_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1827227","volume":"17","author":"C Moltrasio","year":"2026","unstructured":"Moltrasio C, Khan A, Ahmad N, et al. Meta-inflammation in hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches. Front Immunol. 2026;17:1827227. https:\/\/doi.org\/10.3389\/fimmu.2026.1827227.","journal-title":"Front Immunol"},{"issue":"5","key":"1916_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.70085","volume":"33","author":"FS Gruzmark","year":"2025","unstructured":"Gruzmark FS, Beraja GE, Jozic I, et al. Exploring the role of GLP-1 agents in managing diabetic foot ulcers: a narrative and systematic review. Wound Repair Regen. 2025;33(5):e70085. https:\/\/doi.org\/10.1111\/wrr.70085.","journal-title":"Wound Repair Regen"},{"key":"1916_CR29","doi-asserted-by":"publisher","DOI":"10.1055\/a-2858-3774","author":"J Ha","year":"2026","unstructured":"Ha J, Lester ER, De May H, et al. GLP-1 receptor agonist use and wound outcomes after free flap breast reconstruction. J Reconstr Microsurg. 2026. https:\/\/doi.org\/10.1055\/a-2858-3774.","journal-title":"J Reconstr Microsurg"},{"issue":"4","key":"1916_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/SLA.0000000000006614","volume":"281","author":"SZ Aschen","year":"2025","unstructured":"Aschen SZ, Zhang A, O\u2019Connell GM, et al. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Ann Surg. 2025;281(4):600\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000006614.","journal-title":"Ann Surg."},{"key":"1916_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01049-8","author":"MA Visan","year":"2026","unstructured":"Visan MA, Carroll E, Ryan SL, et al. A systematic review of the clinical impact of GLP-1 receptor agonists in hidradenitis suppurativa. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01049-8.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1916_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000257","volume":"12","author":"GB Alqefari","year":"2026","unstructured":"Alqefari GB, Alhameedy MM. Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report. Int J Womens Dermatol. 2026;12(2):e257. https:\/\/doi.org\/10.1097\/JW9.0000000000000257.","journal-title":"Int J Womens Dermatol"},{"key":"1916_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2026.2665732","author":"MJ Ho","year":"2026","unstructured":"Ho MJ, Liew CF, Tan NS, et al. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases. Expert Rev Clin Immunol. 2026. https:\/\/doi.org\/10.1080\/1744666X.2026.2665732.","journal-title":"Expert Rev Clin Immunol"},{"key":"1916_CR34","doi-asserted-by":"crossref","unstructured":"Lishinsky-Fischer N, Amsalem S, Shlomov T, et al. Beyond weight loss: association between GLP-1 receptor agonist therapy and incidence of facial and oculoplastic procedures. Plast Reconstr Surg. 2026.","DOI":"10.1097\/PRS.0000000000013108"},{"key":"1916_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000012405","author":"ZA Koenig","year":"2026","unstructured":"Koenig ZA, Rashid S, Hobbs GR, et al. Perioperative GLP-1 receptor agonist use and surgical outcomes in nonbariatric abdominal panniculectomy: a 10-year retrospective analysis. Plast Reconstr Surg. 2026. https:\/\/doi.org\/10.1097\/PRS.0000000000012405.","journal-title":"Plast Reconstr Surg"},{"key":"1916_CR36","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","volume":"15","author":"S Cedirian","year":"2025","unstructured":"Cedirian S, Donati M, Rapparini L, et al. Benefit-risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons. Dermatol Ther (Heidelb). 2025;15:3173\u201393. https:\/\/doi.org\/10.1007\/s13555-025-01537-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1916_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-00998-3","author":"SM Seyed Jafari","year":"2026","unstructured":"Seyed Jafari SM, Caro G, Lipner SR, et al. The impact of GLP-1 receptor agonists on hair: beneficial effects or adverse outcomes? Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-00998-3.","journal-title":"Am J Clin Dermatol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01916-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:38Z","timestamp":1791446438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01916-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01916-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Caterina M. Giorgio has nothing to disclose. Carola Roman\u00f2 has nothing to disclose. Mariachiara Arisi has nothing to disclose. Mariateresa Rossi is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mariateresa Rossi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Marina Venturini has nothing to disclose. Sara Mezzana has nothing to disclose. Laura Grigolato has nothing to disclose. Benedetta Galli has nothing to disclose. Maria M. Nicoletti has nothing to disclose. Cesare Tomasi has nothing to disclose. Gaetano Licata has nothing to disclose.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review of previously published literature and did not involve new research with human participants or animals.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}